Recombinant polypeptides comprising modified MHC class II DRa1 domains and methods of use
Recombinant polypeptides comprising a modified DRα1 domain are provided. In some embodiments, the polypeptides include the modified DRα1 domain, an antigenic peptide, and optionally a linker sequence. Pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said recombinant polypeptides or pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides are also provided.
1. A recombinant polypeptide comprising a DRα1 domain comprising a glutamine residue at a position corresponding to amino acid position 14 of SEQ ID NO: 1.
2. The recombinant polypeptide of claim 1 , wherein the DRα1 domain is a human DRα1 domain.
3. The recombinant polypeptide of claim 1 , comprising an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 1.
4. The recombinant polypeptide of claim 3 , comprising the amino acid sequence of SEQ ID NO: 1.
5. The recombinant polypeptide of claim 4 , consisting of the amino acid sequence of SEQ ID NO: 1.
6. The recombinant polypeptide of claim 1 , further comprising an antigenic peptide.
7. The recombinant polypeptide of claim 6 , further comprising a linker.
8. The recombinant polypeptide of claim 7 , wherein the linker comprises a peptide linker or a chemical crosslinker.
9. The recombinant polypeptide of claim 7 , wherein the linker comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer.
10. The recombinant polypeptide of claim 6 , wherein the antigenic peptide is MOG-35-55 (oligodendrocyte glycoprotein).
11. The recombinant polypeptide of claim 10 , wherein the MOG-35-55 is human or mouse MOG-35-55.
12. The recombinant polypeptide of claim 10 , wherein the recombinant polypeptide comprises or consists of SEQ ID NO: 2 or SEQ ID NO: 3.
13. A nucleic acid molecule encoding the recombinant polypeptide of claim 1 .
14. An expression construct comprising the nucleic acid of claim 13 .
15. A cell line comprising the expression construct of claim 14 .
16. A pharmaceutical composition comprising:
an effective amount of the recombinant polypeptide of claim 1 ; and
a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16 , wherein the composition comprises at least 5 mg/kg of the recombinant polypeptide.
18. A method of treating an inflammatory disorder comprising administering an effective amount of the pharmaceutical composition of claim 16 to a subject with the inflammatory disorder.
19. The method of claim 18 , wherein the inflammatory disorder is multiple sclerosis or experimental autoimmune encephalopathy (EAE).
20. A pharmaceutical composition comprising:
an effective amount of the nucleic acid molecule of claim 13 ; and
a pharmaceutically acceptable carrier.